Valuation: enGene Therapeutics Inc.

Market Cap 118M 107M 99.48M 89.98M 169M 11.02B 177M 1.2B 477M 5.95B 443M 433M 18.86B P/E 2026 *
-0.96x
P/E 2027 * -1.1x
Enterprise Value -66.57M -60.66M -56.15M -50.79M -95.28M -6.22B -99.72M -679M -269M -3.36B -250M -245M -10.64B EV / Sales 2026 *
-
EV / Sales 2027 * 9.3x
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -
1 day+7.56%
1 week-18.86%
Current month+20.92%
1 month+17.09%
6 months+20.92%
Current year-79.51%
1 week 1.65
Extreme 1.65000000
2.36
1 month 1.45
Extreme 1.45
2.51
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
18.4
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 22/07/2024
Director of Finance/CFO 48 16/07/2026
Chief Administrative Officer 52 09/11/2026
Director TitleAgeSince
Director/Board Member 57 08/08/2023
Director/Board Member 66 18/12/2023
Director/Board Member 66 15/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
22/9/26 Buy

Chief Technology Officer

5,102 0.0076%
16/7/26 Other

Interim Chief Business Officer

75,000 0.1120%
16/7/26 Other

Chief Financial Officer

0 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+7.56%-18.86%-72.63%-75.82% 118M
+0.19%-3.96%+54.92%+69.15% 65.42B
-0.14%-3.20%+7.62%+89.74% 58.91B
+0.06%+0.15%+25.94%+87.89% 55.24B
-0.97%-3.91%+12.98%+113.88% 45.66B
-2.83%-7.58%+15.21%+22.34% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
-0.24%-9.59%+126.05%+647.44% 34.48B
+0.03%-0.93%+76.71%+57.74% 32.5B
+20.58%+22.35%-29.03%+482.03% 31.69B
Average +2.78%-2.24%+23.97%+154.08% 40B
Weighted average by Cap. +1.55%-0.98%+33.36%+154.09%

Financials

2026 *2027 *
Net sales - 4.68M 4.26M 3.95M 3.57M 6.69M 437M 7.01M 47.69M 18.92M 236M 17.55M 17.18M 748M
Net income -125M -114M -106M -95.54M -179M -11.7B -188M -1.28B -506M -6.32B -470M -460M -20.02B -118M -108M -99.72M -90.21M -169M -11.04B -177M -1.21B -478M -5.97B -444M -434M -18.9B
Net Debt -185M -168M -156M -141M -264M -17.23B -276M -1.88B -746M -9.31B -692M -678M -29.5B -74.46M -67.84M -62.8M -56.81M -107M -6.95B -112M -759M -301M -3.76B -279M -274M -11.9B
Projected Income Statement - Annual - enGene Therapeutics Inc.
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
-
Date Price Change Volume
19/11/26 USD 1.760 -4.86% 1,008,095
18/11/26 USD 1.850 +7.56% 2,805,877
17/11/26 USD 1.720 -8.99% 1,730,243
16/11/26 USD 1.890 -21.58% 1,994,847
13/11/26 USD 2.410 +5.70% 3,721,293
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - enGene Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
1.760USD
Average target price
4.286USD
Spread / Average Target
+143.51%
  1. Stock Market
  2. Stocks
  3. ENGN Stock